Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies

Introduction: Subcutaneously administered immunoglobulin (SCIG) is increasingly used to treat patients with primary immunodeficiencies (PIDs). Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparat...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Roger H., Gupta, Sudhir, Melamed, Isaac, Mandujano, J. Fernando, Kobayashi, Ai Lan, Ritchie, Bruce, Geng, Bob, Atkinson, Thomas Prescott, Rehman, Syed, Turpel-Kantor, Eva, Litzman, Jiří
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369354/
https://www.ncbi.nlm.nih.gov/pubmed/30778345
http://dx.doi.org/10.3389/fimmu.2019.00040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369354/
https://www.ncbi.nlm.nih.gov/pubmed/30778345
http://dx.doi.org/10.3389/fimmu.2019.00040

Ejemplares similares